文献速递临床微生物分子诊断

基于二代测序的烟曲霉三唑类耐药预测临床检测方法的开发与验证

Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in Aspergillus fumigatus.
PubMed 文献 · J Clin Microbiol · 2025-07-01

本研究开发并验证了一种基于二代测序的临床检测方法,通过分析烟曲霉cyp51A基因型来预测其对伏立康唑、泊沙康唑、艾沙康唑和伊曲康唑的药敏表型。对109株分离株进行测序并整合14项已发表研究数据制定判读标准,该方法对三唑类野生型菌株的阴性符合率(特异性)≥95%,可快速区分获得性微生物耐药与患者健康状况下降所致的临床耐药。

要点

  • 基于cyp51A基因型的NGS检测可预测烟曲霉对四种三唑类药物的药敏表型。
  • 该方法对三唑类野生型菌株的阴性符合率(特异性)≥95%,可快速排除耐药。
  • 有助于区分微生物学耐药与患者健康下降导致的临床耐药,指导治疗管理。

核心结论

  • 基于cyp51A基因型的二代测序检测能预测烟曲霉对伏立康唑、泊沙康唑、艾沙康唑和伊曲康唑的药敏表型,对三唑类野生型菌株的阴性符合率(特异性)≥95%。

研究设计与样本

  • 研究对109株分离株(包括参考株和来自加州大学洛杉矶分校临床微生物实验室、德克萨斯大学圣安东尼奥健康科学中心真菌检测实验室、美国CDC和FDA抗菌耐药分离株库的临床样本)进行测序,并整合14项已发表研究的数据制定判读标准。

主要发现

  • 尽管cyp51A突变与耐药关联复杂,该三唑类耐药检测方法仍实现了≥95%的阴性符合率(特异性),可推定鉴定三唑类野生型分离株。
  • 该方法能在比传统表型药敏试验更短的时间内提供临床可操作的三唑类野生型鉴定结果。

关键数值与推荐

  • 对三唑类野生型烟曲霉分离株的阴性符合率(特异性)≥95%。

临床怎么用

  • 该检测可快速区分烟曲霉的获得性微生物耐药与患者健康状况下降所致的临床耐药,从而指导最有效的治疗管理。
  • 适用于指导医学复杂患者的三唑类治疗决策,尤其当传统表型药敏试验存在操作、结果判读和报告时间挑战时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rising rates of triazole drug resistance in Aspergillus fumigatus have placed greater reliance on antifungal susceptibility testing (AFST) to guide therapeutic management, particularly in medically complicated patients. Current methods, however, utilize conventional phenotypic assays that may pose significant challenges in performance, result interpretation, and time to reporting. Herein, we developed and validated a next-generation sequencing-based clinical test to predict the AFST phenotype of A. fumigatus against voriconazole, posaconazole, isavuconazole, and itraconazole using the cyp51A genotype as a marker for susceptibility. We sequenced 109 isolates comprising reference and clinical samples from the University of California, Los Angeles, Clinical Microbiology Lab, University of Texas Health Science Center at San Antonio Fungus Testing Laboratory, and the Centers for Disease Control and Prevention and Food and Drug Administration Antimicrobial Resistance Isolate Bank. Additionally, we integrated data from 14 previously published studies to produce comprehensive and robust interpretive criteria for the assay. Despite the complex association between cyp51A mutations and drug resistance, our triazole resistance assay produced a remarkable negative percent agreement (specificity) of ≥95%, thus offering presumptive, yet clinically actionable identification of triazole-wild-type isolates. Clinically, this allows for the rapid discrimination between acquired microbiological resistance in A. fumigatus and observed clinical resistance due to patients' declining health to help guide the most effective therapeutic management.IMPORTANCEThe rising rates of antifungal resistance have been expressed by many as "the silent pandemic," profoundly reshaping the landscape of fungal disease management. Innovations in clinical mycology, however, have remained limited, particularly in comparison to the significant advances seen in the greater field of microbiology. Here, we sought to capitalize upon the expanding utility of next-generation sequencing to address a gap in clinical mycology diagnostics and antifungal susceptibility testing. We developed a whole-genome sequencing protocol to evaluate Aspergillus fumigatus cyp51A genotype to predict phenotypic susceptibility to triazole drugs. Our triazole resistance assay offers clinically actionable identification of triazole-wild-type isolates of A. fumigatus in a much more expeditious timeline than traditional phenotypic susceptibility testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Caldera JR, Dayo A, Wiederhold N, et al. Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in Aspergillus fumigatus. J Clin Microbiol. 2025. PMID: 40590562. doi:10.1128/jcm.00291-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。